PDSB — PDS Biotechnology Share Price
0.000.00%
Last trade - 00:00- $64.45m
- $43.43m
- 21
- 13
- 49
- 17
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.88 | ||
| Price to Tang. Book | 2.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -122.83% | ||
| Return on Equity | -119.22% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Directors
- Stephen Glover NEC (61)
- Frank Bedu-Addo PRE (56)
- Matthew Hill CFO (53)
- Gregory Conn CSO (66)
- Janetta Trochimiuk CTR (58)
- Lauren Wood OTH (61)
- Ilian Iliev DRC (45)
- Kamil Ali-Jackson IND (62)
- Otis Brawley IND (62)
- Gregory Freitag IND (59)
- Richard Sykes IND (78)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- January 22nd, 2009
- Public Since
- October 1st, 2015
- No. of Shareholders
- 37
- No. of Employees
- 24
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 45,710,000
- Address
- 303A College Road East, PRINCETON, 08540
- Web
- https://www.pdsbiotech.com
- Phone
- Contact
- Mike Moyer
- Auditors
- KPMG LLP
Upcoming Events for PDSB
Q3 2025 PDS Biotechnology Corp Earnings Release
Similar to PDSB
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the PDS Biotechnology share price?
As of Today at 22:35 UTC, shares in PDS Biotechnology are trading at $1.41. This share price information is delayed by 15 minutes.
How has the PDS Biotechnology share price performed this year?
Shares in PDS Biotechnology last closed at $1.41 and the price had moved by -53.16% over the past 365 days. In terms of relative price strength the PDS Biotechnology share price has underperformed the S&P500 Index by -58.56% over the past year.
What are the analyst and broker recommendations for PDS Biotechnology?
The overall consensus recommendation for PDS Biotechnology is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the PDS Biotechnology dividend yield?
PDS Biotechnology does not currently pay a dividend.
Does PDS Biotechnology pay a dividend?
PDS Biotechnology does not currently pay a dividend.
When does PDS Biotechnology next pay dividends?
PDS Biotechnology does not currently pay a dividend.
How do I buy PDS Biotechnology shares?
To buy shares in PDS Biotechnology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of PDS Biotechnology?
As of the previous close price of $1.41, shares in PDS Biotechnology had a market capitalisation of $64.45m.
Where are PDS Biotechnology shares listed?
Here are the trading details for PDS Biotechnology:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PDSB
What kind of share is PDS Biotechnology?
Based on an overall assessment of its quality, value and momentum PDS Biotechnology is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a PDS Biotechnology share price forecast for 2025?
The analyst consensus target price for shares in PDS Biotechnology is $7.50. That is 431.91% above the last closing price of $1.41.
Analysts covering PDS Biotechnology currently have a consensus Earnings Per Share (EPS) forecast of -$0.83 for the next financial year.
Find out moreWhat is the trend in the PDS Biotechnology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PDS Biotechnology. Over the past six months, its share price has underperformed the S&P500 Index by -21.1%.
As of the last closing price of $1.41, shares in PDS Biotechnology were trading -26.75% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the PDS Biotechnology PE Ratio?
The PDS Biotechnology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of PDS Biotechnology?
PDS Biotechnology's management team is headed by:
- Stephen Glover - NEC
- Frank Bedu-Addo - PRE
- Matthew Hill - CFO
- Gregory Conn - CSO
- Janetta Trochimiuk - CTR
- Lauren Wood - OTH
- Ilian Iliev - DRC
- Kamil Ali-Jackson - IND
- Otis Brawley - IND
- Gregory Freitag - IND
- Richard Sykes - IND